June 16, 2014

Swine Vets, Researchers Encouraged to Submit Proposals for BIVI PRRS Research Awards

For 12th year, company provides $75,000 to fund three PRRS research studies.

The threat from new or evolving swine diseases serves as a daily reminder to producers and veterinarians of the importance of ongoing applied research in finding effective solutions. For a dozen years, the Boehringer Ingelheim Vetmedica, Inc., (BIVI) Advancement in PRRS Research Awards has helped find practical approaches to managing porcine reproductive and respiratory syndrome (PRRS), a disease costing U.S. swine producers more than $664 million annually in lost production. 

Since 2003, Boehringer Ingelheim Vetmedica, Inc., (BIVI) has contributed more than $900,000 through its Advancement in PRRS Research Awards to fund 37 selected research programs. According to Michelle Sprague, DVM, president of the American Association of Swine Veterinarians (AASV), results from the BIVI-funded research studies have contributed significantly to the industry’s understanding of the disease and how to more effectively manage it. 

“After more than 20 years in North America, PRRS continues to be a major disease challenge for swine veterinarians and producers, and during this time we have learned much about the virus, how it is transmitted and how to better control it,” Sprague says. “Collaborative applied field research will provide the keys to effectively control and eradicate PRRS, helping swine producers raise healthier, more profitable pigs.” 

For its 2015 PRRS Research Awards, the company is again seeking study proposals from swine veterinarians, diagnosticians, and public and private veterinary researchers in the United States, Canada and Mexico. Selected research programs are designed to investigate new ways to diagnose, control and eradicate one of the world’s most costly swine diseases. 

Boehringer Ingelheim encourages people interested in submitting research award proposals to do so by January 1, 2015, and complete details can be found at www.prrsresearch.com. Research award recipients will be announced at the AASV annual meeting in Orlando next March. Proposals will be reviewed by an independent scientific board and awarded based on established criteria including potential economic impact to the swine industry, originality and scientific quality and probability of success in completing the year-long study. 

This year, BIVI recognized three veterinarians and researchers for the 2014 Advancement in PRRS Research Awards program in Dallas. These recipients were Brad Leuwerke, DVM, Swine Vet Center, St. Peter, Minn.; Andres Perez, DVM, Ph.D., University of Minnesota, St. Paul; and Jeff Zimmerman, DVM, PhD, Iowa State University, Ames, Iowa.

To participate in the PRRS research program, submit a proposal, cover sheet, curriculum vitae and two letters of recommendation by January 1, 2015, to: 

Boehringer Ingelheim Vetmedica, Inc.
Attn: Trudy Luther
The Advancement in PRRS Research Award
3902 Gene Field Rd
St. Joseph, MO 64506 USA

For more information and complete submission instructions, please visit the PRRS Research Award website at www.prrsresearch.com.

About Boehringer Ingelheim

Boehringer Ingelheim Vetmedica, Inc., (BIVI) is a leader in the animal health industry with its portfolio of innovative vaccine and pharmaceutical solutions for the prevention and treatment of disease within the swine, cattle, equine and pet markets. BIVI is the U.S. division of the global Boehringer Ingelheim Animal Health GmbH. Our U.S. headquarters are located within the KC Animal Health Corridor in St. Joseph, Mo., with other sites in Ames, Fort Dodge and Sioux Center, Iowa.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates and more than 47,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for the employees and their families and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors of all Boehringer Ingelheim’s endeavors.

With nearly 3,000 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about $1.46 billion (1.07 billion euros) in 2013. In our research-driven Animal Health business, Boehringer Ingelheim continually invests more than 10% of net sales of the Animal Health business in R&D.